Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Urinary incontinence due to neurogenic detrusor overactivity is common in patients with disorders of lower motor neurons controlling the bladder. Multiple sclerosis is a major cause of neurogenic detrusor overactivity, which negatively impacts quality of life. Bladder wall injection of onabotulinum toxin A can diminish spontaneous bladder contraction, urinary urgency, and urge incontinence. Herein we report a 61-year-old woman with multiple sclerosis and autosomal dominant polycystic kidney disease with bladder trabeculation developing after repeated injections of onabotulinum toxin A.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137336 | PMC |
| http://dx.doi.org/10.1016/j.radcr.2018.04.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coenzyme Q10 Supplementation May Be Correlated With Resolution of New Daily Persistent Headache.
J Child Neurol
September 2025
Division of Neurology, The George Washington University/Children's National Hospital, Washington, DC, USA.
New daily persistent headache is a chronic, treatment-resistant primary headache disorder with limited guidance on effective management. Despite its significant impact on headache-related quality of life, few studies have identified targeted therapies that contribute to symptom resolution. This study aims to describe the outcomes of pediatric patients diagnosed with new daily persistent headache and assess associations between specific interventions and headache resolution.
View Article and Find Full Text PDFOnabotulinumtoxinA in the Management of Pain in Adult Patients with Spasticity: A Systematic Literature Review.
Toxins (Basel)
August 2025
Department of Neurology, Yale University, New Haven, CT 06510, USA.
Many patients with spasticity report pain which can be debilitating. Numerous studies have shown onabotulinumtoxinA (onabotA) is efficacious in the management of spasticity but comprehensive data on its impact on spasticity-associated pain is limited. This systematic review aimed to assess the published evidence on the efficacy of onabotA in the management of pain in adults with spasticity.
View Article and Find Full Text PDFBotulinum Neurotoxin A Injections in Spasmodic Entropion: A Clinical Retrospective Cohort Study.
Toxins (Basel)
July 2025
Ophthalmology Department, Tenon Hospital, AP-HP, 4 rue de la Chine, 75020 Paris, France.
While surgical procedure has been considered as the golden standard treatment for spasmodic entropion, Botulinum Neurotoxin A can be indicated in the treatment of spasmodic entropion for fragile elderly patients. This retrospective cohort study included 50 outdoor patients treated for spasmodic entropion, for whom palpebral surgery was recused. The intent of the present study was to describe an alternative outdoor treatment, to detail precisely the Botulinum Neurotoxin (BoNT) treatment pattern, the dosage of BoNT needed, the frequency of re-injection, the efficiency and the complications encountered.
View Article and Find Full Text PDFIatrogenic botulism following botulinum toxin injection: a scoping review of clinical characteristics, risk factors, and dermal considerations.
Cutan Ocul Toxicol
August 2025
Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Study Purpose: Botulinum toxin (BoNT) is commonly used for both cosmetic and medical purposes. However, improper use can lead to iatrogenic botulism. This scoping review aimed to evaluate the systemic and skin-related effects, identify risk factors, and highlight safety gaps in BoNT-related botulism.
View Article and Find Full Text PDFEfficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study.
Eur J Neurol
August 2025
Amgen Inc., Thousand Oaks, California, USA.
Background: Erenumab-induced medication overuse headache (MOH) remission in participants with chronic migraine (CM) in a prospective, Phase 4, randomized, placebo-controlled trial with an open-label treatment period (OLTP). We present 1-year results from the combined double-blind treatment period (DBTP) and OLTP for the stratified nonopioid cohort.
Methods: Participants with CM-MOH were randomized 1:1:1 to subcutaneous 70 or 140 mg erenumab every 4 weeks (QM) or placebo for the initial 24 weeks (DBTP).